Table 2.
Final model parameter estimates and bootstrap results
| Parameter | Estimate | RSE (%) | Bootstrap results * | ||
|---|---|---|---|---|---|
| Median | 95% BI | ||||
| FL3 0 | 70.3 | 1 | 70.2 | 69.0–71.5 | |
| E max | 0.578 | 10 | 0.599 | 0.518–0.701 | |
| T e1/2 (h) | 228 | 35 | 205 | 131–400 | |
| C e50 | 57.0 | 14 | 58.2 | 45.9–78.7 | |
| CV% IIV FL3 0 | 3.08 | 22 | 2.98 | 0.732–4.50 | |
| CV% IIV E max | 9.05 | 49 | 10.07 | 2.07–18.2 | |
| CV% RSE exp | 3.32 | 25 | 2.98 | 1.92–4.24 | |
*
Bootstrap results are derived from 667 successful bootstrap runs.
RSE: relative estimation error; 95% CI: 95% confidence interval derived from the 2.5 and 97.5 percentiles of parameter estimates in successful bootstrap runs; FL30: baseline FL3‐fluorescence value; Emax: maximum increase in FL30 as a consequence of clozapine administration relative to FL30; Te1/2: elimination half‐life; Ce50: clozapine concentration in effect compartment necessary to achieve 50% of the maximum increase in FL3‐fluorescence; CV% IIV: parameter inter‐individual variability expressed as coefficient of variation (%); CV% RSEexp: residual exponential error expressed as coefficient of variation (%).